About: Successful treatment of severe COVID-19 pneumonia with clazakizumab in a heart transplant recipient: case report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Successful treatment of severe COVID-19 pneumonia with clazakizumab in a heart transplant recipient: case report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Successful treatment of severe COVID-19 pneumonia with clazakizumab in a heart transplant recipient: case report
Creator	Chang, David Huang, ; Lawrence, ; Kittleson, Michelle Kobashigawa, Jon Ammerman, Noriko Czer, Lawrence Czer, S Huang, Edmund Jordan, Stanley Kransdorf, Evan Patel, Jignesh Shikhare, Anuja Tran, Hai Vaidya, Gaurang Vo, Ashley Zabner, Rachel
topic	covid:ac7d98b2b45464bdff4e293ba2c3f6f708df1512#this
Source	Elsevier; Medline; PMC
abstract	Abstract Background Severe Acute Respiratory Syndrome caused by coronavirus 2 (SARS-CoV-2) is characterized by an overwhelming cytokine response. Various treatment strategies have been attempted. Methods and Results A 61-year-old male with heart transplantation in 2017 presented with fever, cough, and dyspnea, and confirmed positive for the SARS-CoV-2 disease (COVID-19). Laboratory tests showed significant elevations in C-reactive protein and interleukin-6 (IL-6). Echocardiogram showed LVEF 58% (with EF 57% 6 months prior). Given the lack of clear management guidelines, the patient was initially managed symptomatically. However, the patient subsequently had a rapid respiratory deterioration with worsening inflammatory markers on day 5 of admission. Tocilizumab (anti-IL-6R) was in low supply in the hospital. The patient was offered clazakizumab (anti-IL-6) for compassionate use. Patient received 25 mg intravenously x1 dose. Within 24 hours, he noted significant improvement in symptoms, oxygen requirements, radiological findings and inflammatory markers. There was a transient leukopenia which improved in 4 days. He was discharged home on day 11, with negative nasopharyngeal SARS-CoV-2 PCR as an outpatient on day 35, development of positive serum COVID-19 IgG antibody, and he continued to do well on day 60, with no heart-related symptoms. Conclusion Clazakizumab is a monoclonal antibody against human IL-6, which may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Although not yet FDA approved, it is being investigated for treatment of renal antibody-mediated rejection. Clinical trials of clazakizumab for treatment of COVID-19 are underway worldwide.
has issue date	2020-06-07(xsd:dateTime)
bibo:doi	10.1016/j.transproceed.2020.06.003
bibo:pmid	32563584
has license	els-covid
sha1sum (hex)	ac7d98b2b45464bdff4e293ba2c3f6f708df1512
schema:url	https://doi.org/10.1016/j.transproceed.2020.06.003
resource representing a document's title	Successful treatment of severe COVID-19 pneumonia with clazakizumab in a heart transplant recipient: case report
has PubMed Central identifier	PMC7275980
has PubMed identifier	32563584
schema:publication	Transplant Proc
resource representing a document's body	covid:ac7d98b2b45464bdff4e293ba2c3f6f708df1512#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/ac7d98b2b45464bdff4e293ba2c3f6f708df1512
is schema:about of	named entity 'SARS-CoV-2' named entity '2017' named entity 'SARS-CoV-2' named entity 'LVEF' named entity 'pneumonia' named entity 'Journal' named entity 'GUIDELINES' named entity 'SIGNIFICANT' named entity 'YEAR' named entity 'LACK' named entity 'HAVE' named entity 'Given' named entity 'cytokine' named entity 'dyspnea' named entity 'fever' named entity 'C-reactive protein' named entity 'positive' named entity 'Echocardiogram' named entity 'Laboratory tests' named entity 'IL-6' named entity 'coronavirus 2' named entity 'LVEF' named entity 'pneumonia' named entity 'COVID' named entity 'case report' named entity 'Successful treatment' named entity 'adverse event' named entity 'dyspnea on exertion' named entity 'asymptomatic' named entity 'serum' named entity 'ferritin' named entity 'IL-6' named entity 'PCR' named entity 'interleukin-6' named entity 'pneumonia' named entity 'SARS-CoV-2' named entity 'medical history' named entity 'inflammatory markers' named entity 'neutrophil' named entity 'polymerase chain reaction' named entity 'SARS-CoV-2' named entity 'electrocardiogram' named entity 'IL-6' named entity 'inflammatory state' named entity 'productive cough' named entity 'serum creatinine' named entity 'oxygen therapy' named entity 'clazakizumab' named entity 'observational study' named entity 'Chest X-ray' named entity 'heart transplantation' named entity 'inflammatory markers' named entity 'malignancies' named entity 'troponin' named entity 'clazakizumab' named entity 'blood tests' named entity 'randomized trial' named entity 'ligand' named entity 'tocilizumab' named entity 'rheumatoid arthritis' named entity 'SARS-CoV-2' named entity 'hypotensive' named entity 'transplant recipients'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software